

Resignation of Executive Director

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, announces that Dr Thomas Duthy has given notice of his resignation as an Executive Director of the Company to pursue other business interests.

Dr Duthy's resignation is effective immediately and will see him step down from both his executive and Board duties.

Dr Duthy has served Neurotech since September 2022, guiding the Company through significant progress spanning clinical and corporate development, which included assisting in raising \$19.0 million in capital to support the strategy.

Neurotech Non-Executive Chairman Mark Davies commented: *"Tom has provided outstanding service to Neurotech as it evolved from a prospective, early-stage business into an advanced drug development Company focused on paediatric neurological disorders with significant commercial potential. On behalf of the Board I want to thank Tom for his tireless contribution to the Company and wish him all the best moving forward."*

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.